Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability
Open Access
- 3 May 2022
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 327 (17) , 1647-1648
Abstract
This Viewpoint documents the history, value, and success of the 340B Pricing Program, which is under threat from pharmaceutical corporations’ withdrawal and from a pending Supreme Court decision and offers 2 legislative fixes to address the concerns raised by the pharmaceutical companies.Keywords
This publication has 3 references indexed in Scilit:
- US Supreme Court Review of the 340B Drug Discount Program—American Hospital Association v BecerraJAMA Health Forum, 2022
- Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing ProgramPLOS ONE, 2019
- Diversity of Participants in the 340B Drug Pricing Program for US HospitalsJAMA Internal Medicine, 2018